MAURICIO SIMOES ABRAO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Principles of safe laparoscopic entry(2016) DJOKOVIC, Dusan; GUPTA, Janesh; THOMAS, Viju; MAHER, Peter; TERNAMIAN, Artin; VILOS, George; LODDO, Alessandro; REICH, Harry; DOWNES, Ellis; RACHMAN, Ichnandy Arief; CLEVIN, Lotte; ABRAO, Mauricio S.; KECKSTEIN, Georg; STARK, Michael; HERENDAEL, Bruno van
- Role of cytochrome P450 2C19 polymorphisms and body mass index in endometriosis: A case-control study(2017) CARDOSO, Jessica Vilarinho; ABRAO, Mauricio Simoes; BERARDO, Plinio Tostes; FERRARI, Renato; NASCIUTTI, Luiz Eurico; MACHADO, Daniel Escorsim; PERINI, Jamila AlessandraObjective: To investigate the contribution of CYP2C19 polymorphisms and body mass index (BMI) in the development of endometriosis. Study design: This is a case-control study that includes 356 women (187 cases and 169 controls) recruited from two hospitals in the Brazilian public health system. The genotyping analyses of the CYP2C19*2 and CYP2C19*17 polymorphisms were performed using TaqMan allelic discrimination assays, and the association of the studied polymorphisms with endometriosis was evaluated by multivariate logistic regression. Pearson correlation coefficients were used to investigate the interaction between BMI and CYP2C19 polymorphisms. Results: The variant allele frequencies of CYP2C19*2 were significantly different between cases and controls, and after adjusting for confounding factors, the CYP2C19*2 polymorphism was more frequent in women with endometriosis, considering all cases (CYP2C19*2: OR = 1.83; 95% CI = 1.17-2.85) and only deeply infiltrating endometriosis (DIE) cases (CYP2C19*2: OR = 2.32; 95% CI = 1.42-3.77). BMI was significantly lower in endometriosis patients (26.5 +/- 4.68) than in controls (27.8 +/- 5.65, P < 0.02). Among obese women (BMI 30-40), the CYP2C19*2 polymorphism had a greater association with endometriosis (CYP2C19*2: OR = 3.27; 95% CI = 1.55-6.89). There was a positive correlation between CYP2C19*2 and BMI 30-40 (P = 0.004). Conclusions: The findings of our study suggest that CYP2C19*2 is positively associated with endometriosis and that BMI may have a significant interaction with CYP2C19*2 and the risk of endometriosis.
- Deep endometriosis: Can surgical complexity and associated risk factors be evaluated with transvaginal sonography and classification systems?(2022) AAS-ENG, Mee Kristine; KECKSTEIN, Joerg; CONDOUS, George; ABRAO, Mauricio S.; HUDELIST, GernotDeep endometriosis (DE) surgery often requires advanced knowledge in laparoscopic surgery due to the location of affected organs such as the bowel, vagina, rectovaginal space including adjacent nerve structures, ureters and urinary bladder. Patients are at risk of serious complications and sequelae like anastomotic leakage, rectovaginal fistula and voiding dysfunction. Detailed knowledge of disease extent and location by transvaginal sonography (TVS) can aid the clinician to pre-operatively plan complex surgeries and estimate associated risks. Classification systems like #Enzian can be used in combination with TVS to assess surgical risk factors.
- Combined effect of vascular endothelial growth factor and its receptor polymorphisms in endometriosis: a case-control study(2017) CARDOSO, Jessica Vilarinho; ABRAO, Mauricio Simoes; VIANNA-JORGE, Rosane; FERRARI, Renato; BERARDO, Plinio Tostes; MACHADO, Daniel Escorsim; PERINI, Jamila AlessandraObjective: Endometriosis is a multifactorial gynecological disease, whose pathogenesis is crucially dependent on angiogenesis, which is signaled via vascular endothelial growth factor (VEGF) and its receptor (VEGFR2). We hypothesize that single nucleotide polymorphisms (SNPs) in VEGF and VEGFR2 genes may influence the onset and/or the progression of endometriosis. The main aim of this study was to investigate the contribution of VEGF and VEGFR2 SNPs as risk factors for endometriosis, as well as their association with endometrioSis symptoms. Study design: A case-control study was conducted, involving 293 endometriosis patients and 223 controls, who were submitted to laparoscopic or laparotomy surgery at hospitals from the Brazilian public health system. Genotyping of VEGF (-2578C>A, -460T>C, -1154G>A, +405G>C and +936C>T) and VEGFR2 (-604T>C, 1192C>T) SNPs was performed by TaqMan real-time polymerase chain reaction. The association between SNPs and endometriosis, deep infiltrating endometriosis (DIE) or endometriosis symptoms was estimated by odds ratios (OR) with their 95% confidence intervals (CI), which were calculated using multivariate logistic regression models. Results: VEGF variant alleles -2578A and -1154A were associated with increased endometriosis risk (OR: 1.39, 95% CI: 1.04-1.87 and OR: 1.63, 95% CI: 1.12-2.37, respectively), whereas VEGF 405C and VEGFR2 1192T were associated with lower risk of endometriosis (OR: 0.66, 95% CI: 0.43-1.00 and OR: 0.58, 95% CI: 0.40-0.84, respectively). The combination of wild-type genotypes of both VEGF -2578C>A and -1154G>A with variant genotypes of both VEGF +405G>C and VEGFR2 1192C>T showed the best protective effect against the development of endometriosis, either considering all cases (OR: 0.33, 95% CI: 0.12-0.89) or only DIE (OR: 0.30, 95% CI: 0.10-0.87). The combination of variant genotypes of VEGF -2578C>A, -1154G>A, +405G>C and VEGFR2 1192C>T was also protective against DIE (OR: 0.67, 95% CI: 0.46-0.96). VEGFR2 1192C>T were associated with reduced cyclical urinary complaints (OR: 0.40, 95% CI: 0.18-0.88). Conclusions: Our results indicate that VEGF SNPs -2578C>A and -1154G>A increase endometriosis risk, whereas VEGF +405G>C and VEGFR2 1192C>T are protective against disease development, with VEGFR2 1192C>T also reducing cyclical urinary symptoms. The combined analysis of VEGF-VEGFR2 genotypes suggests a gene-gene interaction in endometriosis susceptibility.
- HLA-G is upregulated in advanced endometriosis(2019) RACHED, Marici R.; COELHO, Veronica; MARIN, Maria Lucia C.; PINCERATO, Kstja; FUJITA, Andre; KALIL, Jorge E.; ABRAO, Mauricio S.Objective: To assess whether the HLA-G immunomodulatory protein is potentially involved in the pathophysiology of endometriosis or disease progression. Study design: Cross-sectional observational study of 227 women who underwent laparoscopy, being 146 for endometriosis excision and 81 for elective tubal ligation (control group). Soluble HLA-G (sHLA-G) levels in the serum and peritoneal fluid (PF), as well as the HLA-G protein expression in matched eutopic and ectopic endometrium of women with and without endometriosis were evaluated by ELISA and immunohistochemistry assays, respectively. Women with endometriosis were separated into groups according to the initial (I/II, n=60) and advanced (III/IV, n=86) stages of disease. sHLA-G measurement was performed only in women with matched serum and PF samples in both the control (CTRL; n=77) and endometriosis (EDT; I-II, n=60; n=83) groups. HLA-G protein expression was evaluated in 26 women with deep endometriosis (I-II, n=12; III-IV, n=14) and 22 controls. Results: Higher concentrations of sHLA-G (P=0.013) in the serum but not in the PF were observed in women with advanced endometriosis compared to the control group. In situ expression of HLA-G protein was also higher in ectopic (P=0.018) but not in eutopic endometrium of women with advanced endometriosis compared to control group. Conclusion: Our findings suggest that HLA-G upregulation in advanced stages may contribute to the state of immunosuppression in endometriosis as disease progresses.
- Could statins constitute a novel treatment for endometriosis? Systematic review of the literature(2014) GIBRAN, Luciano; MARANHAO, Raul C.; ABRAO, Mauricio S.; BARACAT, Edmundo C.; PODGAEC, SergioEndometriosis, defined as the presence of endometrial glands and/or stroma outside the uterine cavity, is an estrogen-dependent disease that affects about 10% of reproductive age women. Theories to explain the etiology of endometriosis abound. These include the alteration of epithelial cells on peritoneal surface, metaplasia of embryonic remnants of the mullerian ducts, immune system abnormalities, and the dissemination of endometrial cells through the circulation or lymphatic system, as well as retrograde menstruation, the hypothesis currently favored for the development of endometriosis. Angiogenesis, the development of new capillaries from pre-existing blood vessels, has been proposed as a key mechanism in the pathogenesis of endometriosis. Again from an etiological perspective, the formation of endometriotic implants requires ectopic fixation and proliferation of endometrial stroma and glands. The process of invasive insertion of endometriotic tissues involves the degradation of the extracellular matrix, and altered expression of matrix metalloproteinases (MMPs) in the eutopic and ectopic endometrium. Considering the antiproliferative, antiangiogenic, antioxidant, anti-inflammatory properties and matrix metalloproteinase activity inhibition of statins and the original studies addressing the possible mechanisms of action in endometriosis, the aim of this systematic review was to synthesize the research conducted to date in order to propose statins as possible and effective tools for controlling this disease.